fbpx

Nyheder

Lundbeckfonden Ventures nyheder

Cambridge, UK and Indianapolis, US – 25 April 2019: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”) (EURONEXT: ACPH) announces that additional data and analyses from its positive Phase 3 clinical trial of BARHEMSYS® (intravenous amisulpride) as a rescue treatment of established post-operative nausea & vomiting (PONV) will be presented today in a poster at...
Lund, Sweden, 17.30 CET, 24 April 2019 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids, today announces that Vikram Johri will leave his role as GM & EVP Commercial Operations Eurow and BONESUPPORT as of today. On an interim basis all positions having reported into the GM & EVP Commercial...
BONESUPPORTs annual report for 2018 is now available as a pdf on the group’s web page, www.bonesupport.com. A PDF-version is also attached to this press release. About BONESUPPORT™ BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs....
Lund, Sweden, 16.00 CET, April 16, 2019 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids, today announced that the quarterly report for the first quarter of 2019 will be published on May 2 at 08.00 CET instead of as previously communicated on 8 May. This is due to the fact...
Presentation of data from multiple preclinical studies from APX001 antifungal program SAN DIEGO – April 12, 2019 – Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, announced today that three posters from the APX001 development program will be presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), being held...
Lund, Sweden, 08.00 CET, 10 April 2019 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids, today announced the publication of new radiographic and histological data, which for the first time provides clinical evidence of CERAMENT® remodeling into bone in humans. “This publication describes for the first time in detail radiographic...
CAMBRIDGE, Mass.–(BUSINESS WIRE)– Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that it closed a $40 million Series D financing. New investor Medicxi led the round, with current investors also participating. The Company plans to use the proceeds from the Series D financing to support the late...
Lund, Sverige, 18:00 CET, 29 March 2019 – During the month of March, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased due to directed issue and repurchase of 505,000 series C shares, which were resolved upon by the board of directors on 1 March 2019 pursuant to the authorizations granted...
CAMBRIDGE, Mass., March 29, 2019 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for SPR994, Spero’s lead...
1 2 3 4 5 58

Lundbeckfonden Ventures

Nyheder

Acacia Pharma Group PLC – Acacia Pharma Group plc – Issue of Equity on Exercise of Options
16. august 2019
Acacia Pharma Group PLC – Acacia Pharma Group plc: Notice of Interim Results
12. august 2019
Change in number of shares and votes in BONESUPPORT HOLDING AB (publ)
31. juli 2019